A personal view of some controversies in allocating treatment to patients in clinical trials | Zendy

Senn Stephen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

A personal view of some controversies in allocating treatment to patients in clinical trials

Author(s) -

Senn Stephen

Publication year - 1995

Publication title -

statistics in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.996

H-Index - 183

eISSN - 1097-0258

pISSN - 0277-6715

DOI - 10.1002/sim.4780142406

Subject(s) - statistician , blinding , clinical trial , selection (genetic algorithm) , randomization , drug development , intensive care medicine , computer science , medicine , psychology , drug , artificial intelligence , psychiatry , pathology

A non‐exhaustive but nevertheless wide‐ranging if biased and personal view of various matters affecting the allocation of treatments to patients in controlled clinical trials will be undertaken from the standpoint of a statistician working in drug development. The following topics are considered: the use of ‘placebos’ in the run‐in phase; the use of crossover trials; selection of patients; various matters concerning centres; two extreme alternatives to randomization, and various matters linking blinding and allocation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research